Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 12, 2024
Management Tracks
Two more C-suite hires at Xaira
Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus
BioCentury | Oct 17, 2024
Product Development
Wave data propel RNA-editing stocks, but are all platforms created equal?
In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
BioCentury | Sep 26, 2024
Finance
Eyes on Europe: Asabys’ €180M fund, Genespire’s record series B
BioCentury’s weekly Venture Report also includes Arch’s latest fund, Flagship-backed Mirai, series Bs for Vicebio and 858, and more
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Sep 20, 2023
Finance
Sept. 19 Quick Takes: RNA editing company Airna emerges with $30M round led by Arch
Plus: Longevity-focused VC debuts and updates from Recode, Merck, Taysha and Paratek
BioCentury | Mar 17, 2023
Discovery & Translation
RNA origami to aid delivery; plus sense-and-response ADAR base editing and more
BioCentury's roundup of translational news
BioCentury | Mar 2, 2023
Discovery & Translation
Merck’s HIV reservoir-reducing compounds; plus an anti-IL-8 mAb for endometriosis and more
BioCentury's roundup of translational news
BioCentury | Oct 7, 2022
Discovery & Translation
Galixir’s rapid PROTAC design; plus Engimmune’s TCR platform and more
BioCentury’s roundup of translational news
BioCentury | Mar 9, 2022
Discovery & Translation
Wave takes its next-gen oligos beyond gene silencing and splicing
Preclinical data suggest the oligos can be used for base editing and modulating protein-protein interactions
BioCentury | Feb 12, 2022
Discovery & Translation
More efficient RNA base editing, TCR constructs targeting WT1 epitopes and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 27